D-Sight, member of CataloniaBio & HealthTech, has been selected among more than 150 applications from 18 European countries as one of the most innovative and promising projects in Europe for this year’s edition of the InnoStars Awards. Together with another 18 participants from different European countries, the spin-off company has worked diligently on conceptualizing key aspects of its business plan and advancing the preclinical development of its drug for the treatment of early stages of diabetic retinopathy.
The competitive and innovative value of the project under development by D-Sight was recognized by the jury members and the company was selected as a finalist for the InnoStars Awards Final Pitch Competition that took place the past 8th of November at the Milano Innovation District (MIND) in Milan (Italy).
Following a thrilling competition among ten highly innovative and disruptive technological and biomedical start-ups in the health sector, D-Sight was honored to receive an award of 10.000€ as part of the EIT Health InnoStars Awards 2023. This award is a recognition from investors and the international EIT Health community of the human and scientific talent leading this project, as well as the high competitive and innovative potential of the treatment being developed by D-Sight. The strategic alliances formed during this program will enable the successful transfer of this technology to the market.
D-Sight is a spin-off company from Vall d’Hebron Institute of Research (VHIR) lead by an experienced and committed team dedicated to the discovery and development of new innovative treatments for neurodegenerative diseases of the retina. D-Sight is shaping the future of retinal diseases treatment with their first product in development: a first-in-class eye drop formulation for the prevention and treatment of diabetic retinopathy in its early stages.
Comments